Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Employees

272

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	$0.0289	0.00%	1,267
27/10/26	$0.0289	+15.14%	43,846
26/10/26	$0.0251	-16.33%	340,808
23/10/26	$0.0300	+20.00%	41,951
22/10/26	$0.0250	-21.87%	628,856

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adaptimmune Therapeutics plc

Company calendar

Delayed OTC Markets 18:57:26 28/10/2026 +04			5-day change	1st Jan Change
0.0289 ^USD	0.00%		-9.69%	+11.15%

05-19	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI

Market Cap	7.66M 6.87M 6.35M 5.76M 10.76M 728M 10.89M 76.11M 30.23M 381M 28.75M 28.14M 1.21B	P/E 2024	-1.8x	P/E 2025	0.33x
Enterprise Value	-4.21M -3.78M -3.49M -3.16M -5.91M -400M -5.98M -41.82M -16.61M -210M -15.8M -15.46M -665M	EV / Sales 2024	0.34x	EV / Sales 2025	-0.84x
Free-Float	14.03%	Yield 2024 *	-	Yield 2025	-

05-19	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI
11-17	Adaptimmune Therapeutics plc Announces Leadership Changes	CI
27/10/25	Evaxion Names Helen Tayton-Martin as Chief Executive Officer	MT
27/10/25	Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index	CI
24/10/25	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	MT
23/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
22/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
21/10/25	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT
20/10/25	Top Midday Decliners	MT
20/10/25	European Equities Close Mostly Higher in Monday Trading; UK Sentiment Sees 'Some of the Gloom Lift'	MT
20/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
20/10/25	Adaptimmune Therapeutics to Voluntarily Delist From Nasdaq	MT

30/07/25	Guggenheim Downgrades Adaptimmune Therapeutics to Neutral From Buy	MT
29/07/25	HC Wainwright Downgrades Adaptimmune Therapeutics to Neutral From Buy	MT
26/06/25	Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns	MT
27/11/24	Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating	MT
30/07/24	HC Wainwright Starts Adaptimmune Therapeutics With Buy Rating, $4 Price Target	MT

Adaptimmune Therapeutics plc Stock

Stocks

ADAPY

US00653A1079

Pharmaceuticals

Valuation: Adaptimmune Therapeutics plc

Chart: Adaptimmune Therapeutics plc

Latest news: Adaptimmune Therapeutics plc

Analysts' recommendations: Adaptimmune Therapeutics plc

Press Releases: Adaptimmune Therapeutics plc

News in other languages: Adaptimmune Therapeutics plc

Quotes and Performance

Price Extremes

Managers and Directors: Adaptimmune Therapeutics plc

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

11-17	Adaptimmune Announces Changes to Board and Executive Leadership Team	NE
20/10/25	Adaptimmune Announces Delisting from Nasdaq	NE
13/08/25	Adaptimmune Reports Q2 Financial Results and Provides Business Update	NE
28/07/25	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds	NE
13/05/25	Adaptimmune Reports Q1 Financial Results and Provides Business Update	NE

31/05/24	Galapagos gaat samenwerken met Adaptimmune
12/04/24	Roche: Genentech met fin à la collaboration avec Adaptimmune Therapeutics
12/04/24	Roche-Tochter Genentech beendet Zusammenarbeit mit Adaptimmune Therapeutics
11/04/23	GSK : Adaptimmune reprend les droits de deux programmes
07/09/21	Aktien Schweiz Schluss: SMI unter Druck

1 week	-9.69%
Current month	-23.95%
1 month	+7.84%
3 months	-12.42%
6 months	+725.71%
Current year	+11.15%

1 week	0.02	0.03
1 month	0	0.04
Current year	0	0.05
1 year	0	0.07
3 years	0	2.05
5 years	0	5.95
10 years	0	14.62

Manager	Title	Age	Since
Christopher Hill CEO	Chief Executive Officer	46	14/11/2025
Juli P. Miller IRC	Investor Relations Contact	-	01/08/2016
Phil Bassett PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Lawrence Alleva CHM	Chairman	76	14/11/2025
Garry Menzel BRD	Director/Board Member	61	01/06/2023
Christopher Hill BRD	Director/Board Member	46	14/11/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/25	Gavin Wood	Sell	Chief Financial Officer	96,000	0.0060%
28/08/25	William Bertrand	Sell	Compliance Officer	207,000	0.0130%
15/08/25	NEA Management Co. LLC	Sell	Company	19,500,000	7.3571%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADAPTIMMUNE THERAPEUTICS PLC	0.00%	-9.69%	-46.38%	-94.79%	7.66M
ELI LILLY AND COMPANY	+0.92%	+2.04%	+58.11%	+129.20%	1,143B
JOHNSON & JOHNSON	+1.19%	+5.46%	+45.43%	+84.90%	647B
ABBVIE INC.	+0.55%	+1.32%	+26.82%	+103.37%	506B
ROCHE HOLDING AG	+0.01%	+1.84%	+52.89%	+65.44%	384B
MERCK & CO., INC.	+0.01%	-5.37%	+62.97%	+38.13%	350B
NOVARTIS AG	+1.16%	+2.81%	+31.93%	+54.13%	293B
ASTRAZENECA PLC	+0.44%	+2.39%	+4.11%	+26.40%	265B
AMGEN INC.	+1.09%	+3.35%	+55.10%	+72.13%	242B
GILEAD SCIENCES, INC.	+0.66%	+4.60%	+36.27%	+106.54%	197B
Average	+0.58%	-0.35%	+32.72%	+58.55%	402.75B
Weighted average by Cap.	+0.70%	+0.71%	+45.36%	+88.08%

	2024	2025
Net sales	178M 160M 148M 134M 250M 16.91B 253M 1.77B 702M 8.86B 668M 654M 28.11B	5.92M 5.32M 4.91M 4.45M 8.32M 563M 8.42M 58.86M 23.38M 295M 22.24M 21.76M 935M
Net income	-70.81M -63.56M -58.68M -53.22M -99.46M -6.73B -101M -704M -279M -3.53B -266M -260M -11.18B	25.21M 22.62M 20.89M 18.94M 35.4M 2.39B 35.84M 250M 99.46M 1.25B 94.62M 92.59M 3.98B
Net Debt	-77.4M -69.46M -64.14M -58.16M -109M -7.35B -110M -769M -305M -3.85B -291M -284M -12.22B	-11.87M -10.65M -9.84M -8.92M -16.67M -1.13B -16.88M -118M -46.83M -591M -44.55M -43.6M -1.87B